James Ford

Clinical Trials

• Not Recruiting Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
• Not Recruiting Combination SBRT (Stereotactic Body Radiotherapy) With TACE (Transarterial Chemoembolization) for Unresectable Hepatocellular Carcinoma
• Not Recruiting Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
• Not Recruiting Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
• Recruiting Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer
• Recruiting Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
• Recruiting Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia
• Recruiting Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
• Not Recruiting A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer
• Recruiting Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
• Not Recruiting Safety Study of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
• Recruiting Molecular Genetic and Pathological Studies of Anal Tumors
• Recruiting Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
• Not Recruiting Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
• Not Recruiting A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
• Not Recruiting Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
• Not Recruiting Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
• Not Recruiting A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer
• Not Recruiting Study of GSK1363089 in Metastatic Gastric Cancer
• Not Recruiting Trilogy Stereotactic Body Radiotherapy for Pancreatic Cancer
• Not Recruiting A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
• Not Recruiting A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
• Not Recruiting Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer
• Not Recruiting Assessment of Health Related Quality of Life in Patients Treated for Rectal Cancer
• Not Recruiting Phase II Trial - Breast Cancer Chemoprevention by Lovastatin
• Recruiting The Gastric Cancer Foundation: A Gastric Cancer Registry
• Recruiting Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors